TrademarkOpen
Search / United States / 97979331

Heads up: we show every live trademark, plus inactive ones from the last 5 years, in the United States, Singapore, Canada, Australia and France. India is looked up live when you search, so it is not a saved copy of every mark, and it can be busy some days. Data is only as fresh as each country publishes it, and some countries aren’t included yet, so a brand can be registered even if it doesn’t show here. Always check the official record before you use a name. This is not legal advice.

🇺🇸 United States · Trademark / Service Mark

C.

Registered
Used for: human pharmaceuticals for the treatment of cardiovascular diseases, diseases and conditions associated with cardiac…
Show more

Class 5: human pharmaceuticals for the treatment of cardiovascular diseases, diseases and conditions associated with cardiac muscle dysfunction, cardiac muscle wasting, cardiac muscle atrophy, cardiac muscle weakness
Class 42: research in the field of cellular assay screening and pharmaceutical discovery and development

Class 5 – Pharmaceuticals & supplementsClass 42 – Technology & SaaS

Status timeline

  1. 10 Mar 2022
    Application filed
    New Application Entered
  2. 17 Dec 2022
    Assigned to an examining attorney
    Assigned To Examiner
  3. 19 Dec 2022
    Approved for publication
    Approved For Pub - Principal Register
  4. 24 Jan 2023
    Published for opposition
    Published For Opposition
  5. 21 Mar 2023
    Notice of allowance issued — statement of use required
    Noa Mailed - Sou Required From Applicant
  6. 7 Sep 2023
    Statement-of-use extension 1 granted
    Sou Extension 1 Granted
  7. 12 Mar 2024
    Statement-of-use extension 2 granted
    Sou Extension 2 Granted
  8. 20 Aug 2024
    Statement-of-use extension 3 granted
    Sou Extension 3 Granted
  9. 20 Aug 2024
    Statement of use filed
    Teas Statement Of Use Received
  10. 23 Nov 2024
    Office action issued
    Non-Final Action Written
  11. 12 Feb 2025
    Response to office action filed
    Teas Response To Office Action Received
  12. 20 Feb 2025
    Statement of use accepted
    Allowed Principal Register - Sou Accepted
  13. 11 Mar 2025
    Registered on the Principal Register
    Registered-Principal Register
All 39 events
2025-03-11Registered-Principal Register
2025-03-11Notice Of Registration Confirmation Emailed
2025-02-20Assigned To Lie
2025-02-20Correspondence Received In Law Office
2025-02-20Teas/Email Correspondence Entered
2025-02-20Allowed Principal Register - Sou Accepted
2025-02-20Notice Of Acceptance Of Statement Of Use E-Mailed
2025-02-12Teas Response To Office Action Received
2024-11-23Non-Final Action Written
2024-11-23Non-Final Action E-Mailed
2024-11-23Notification Of Non-Final Action E-Mailed
2024-11-22Divisional Processing Complete
2024-11-22Statement Of Use Processing Complete
2024-10-24Case Assigned To Intent To Use Paralegal
2024-08-20Sou Teas Extension Received
2024-08-20Sou Extension 3 Filed
2024-08-20Sou Extension 3 Granted
2024-08-20Notice Of Approval Of Extension Request E-Mailed
2024-08-20Teas Statement Of Use Received
2024-08-20Teas Request To Divide Received
2024-08-20Divisional Request Received
2024-08-20Use Amendment Filed
2024-03-13Notice Of Approval Of Extension Request E-Mailed
2024-03-12Sou Teas Extension Received
2024-03-12Sou Extension 2 Filed
2024-03-12Sou Extension 2 Granted
2023-09-09Notice Of Approval Of Extension Request E-Mailed
2023-09-07Sou Teas Extension Received
2023-09-07Sou Extension 1 Filed
2023-09-07Sou Extension 1 Granted
2023-03-21Noa Mailed - Sou Required From Applicant
2023-01-24Published For Opposition
2023-01-24Official Gazette Publication Confirmation E-Mailed
2023-01-04Notification Of Notice Of Publication E-Mailed
2022-12-19Approved For Pub - Principal Register
2022-12-17Assigned To Examiner
2022-03-12Notice Of Design Search Code E-Mailed
2022-03-11New Application Office Supplied Data Entered
2022-03-10New Application Entered

Goods & services by class

Class 5 Pharmaceuticals & supplements

human pharmaceuticals for the treatment of cardiovascular diseases, diseases and conditions associated with cardiac muscle dysfunction, cardiac muscle wasting, cardiac muscle atrophy, cardiac muscle weakness

First use anywhere 5 Jun 2023 · First use in commerce 5 Jun 2023

Class 42 Technology & SaaS

research in the field of cellular assay screening and pharmaceutical discovery and development

First use anywhere 0 Sep 2015 · First use in commerce 0 Sep 2015

Owner details

See the official record for contact details. View official record →

Source & freshness

Source: the official United States trademark register. This record was last updated on 11 Mar 2025; the index was built on 20 Nov 2026 and covers data through 31 Aug 2026. View official record → If the two differ, the official record is correct.